Blockade with a specific KIR2DL-1,2/3 mAb reversed NK-cell inhibition and significantly enhanced degranulation and IFN-γ production of IL-2-preactivated NK-cells in the presence of primary glioblastoma (GBM) cells (95). The gene discussed is IFNG; the disease is glioblastoma.